879403-42-6

Basic information

• Product Name: (S)-N-Boc-2-aminomethylmorpholine
• Synonyms: (S)-N-Boc-2-aminomethylmorpholine;(S)-4-N-Boc-2-aminomethylmorpholine;(S)-4-Boc-2-aminomethylmorpholine;(S)-2-AMinoMethyl-4-Boc-Morpholine;(S)-2-(Aminomethyl)morpholine-4-carboxylic acid tert-butyl ester;4-Morpholinecarboxylic acid, 2-(aMinoMethyl)-, 1,1-diMethylethyl ester, (2S)-;(S)-tert-Butyl 2-(aMinoMethyl)Morpholine-4-carboxylate;tert-butyl (2S)-2-(aminomethyl)morpholine-4-carboxylate
• CAS NO: 879403-42-6
• Molecular Formula: C₁₀H₂₀N₂O₃
• Molecular Weight: 216.279
• Mol File: 879403-42-6.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 311℃
• Flash Point: 141℃
• Appearance: /
• Density: 1.078
• Vapor Pressure: 0.000589mmHg at 25°C
• Refractive Index: 1.477
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 9.37±0.29(Predicted)
• CAS DataBase Reference: (S)-N-Boc-2-aminomethylmorpholine(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-N-Boc-2-aminomethylmorpholine(879403-42-6)
• EPA Substance Registry System: (S)-N-Boc-2-aminomethylmorpholine(879403-42-6)

Safety Data

• Hazardous Substances Data: 879403-42-6(Hazardous Substances Data)

Usage

General Description

(S)-N-Boc-2-Aminomethylmorpholine is a chemical compound used in the pharmaceutical industry for the synthesis of various drugs and pharmaceuticals. It is a derivative of morpholine and contains a Boc (tert-butyloxycarbonyl) protective group on the nitrogen atom. The compound has a chiral center and exists as a single enantiomer. (S)-N-Boc-2-Aminomethylmorpholine is known for its use as a building block in the preparation of various biologically active molecules, and it is valued for its ability to introduce the morpholine ring into complex chemical structures. It is also used as a ligand in asymmetric synthesis and catalysis.

InChI:InChI=1/C10H20N2O3/c1-10(2,3)15-9(13)12-4-5-14-8(6-11)7-12/h8H,4-7,11H2,1-3H3/t8-/m0/s1

Upstream product

• 919286-58-1 tert-butyl (2R)-2-(bromomethyl)morpholine-4-carboxylate 
• 135065-64-4 tert-butyl (2R)-2-({[(4-methylphenyl)sulfonyl]oxy}methyl)morpholine-4-carboxylate 
• 1308849-91-3 (S)-tert-butyl 2-((1,3-dioxoisoindolin-2-yl)methyl)morpholine-4-carboxylate 
• 503455-76-3 (R)-tert-butyl 2-(((methylsulfonyl)oxy)methyl)morpholine-4-carboxylate 
• 135065-71-3 (R)-2-hydroxymethylmorpholine-4-carboxylic acid tert-butyl ester 
• 921211-91-8 tert-butyl (2R)-2-(azidomethyl)morpholine-4-carboxylate 

Downstream Products

• 1308849-92-4 (S)-tert-butyl 2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-5-methyl-1H-benzo[d]imidazol-1-yl)methyl)morpholine-4-carboxylate 
• 1308849-86-6 (S)-methyl 2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-5-methyl-1H-benzo[d]imidazol-1-yl)methyl)morpholine-4-carboxylate 

Relevant articles and documents

BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF

The present disclosure relates to benzimidazole derivatives, a preparation method therefor and a medical use thereof. Specifically, the present disclosure relates to a benzimidazole derivative represented by the general formula (I), a preparation method therefor, a pharmaceutical composition containing the derivative, and its use as a therapeutic agent, in particular its use for the treatment of diseases related to P2X3 activity.

Solid dispersions containing an apoptosis-inducing agent

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

BENZOIMIDAZOLE COMPOUNDS AND USES THEREOF

This invention generally relates to substituted benzoimidazole compounds, particularly methyl 2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-5-methyl-1H- benzo[d]imidazol-1-yl)methyl)morpholine-4-carboxylate and salts thereof. This invention also relates